European regulators have denied approval for Sarepta-Roche’s gene therapy candidate, Elevidys, sending the company’s shares tumbling. The decision highlights the regulatory hurdles facing cutting‐edge biotech and the ensuing financial backlash, leaving investors to wonder if innovation comes at too high a price.
Back to Top / Friday, July 25, 2025, 10:21 am / permalink 10913 / 0 stories in 7 months
Gilead to acquire Arcellx for $7.8 billion in cash deal / 11 days
ArcaScience secures $7M for AI-powered drug development innovation / 6 months
Bitpanda Snubs London IPO Amid Shifting Global Market / 6 months
Lilly’s obesity pill data stirs conflicting market reactions / 6 months
Novo Nordisk Forecast Slashed, Shares Plunge Sharply / 7 months
One Biosciences Secures €15M Series A for Precision Oncology / 7 months
Anne Wojcicki reclaims 23andMe with a surprise multi‐million dollar buyback / 8 months
NorthFeed Inc.
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.